Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 17/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22324243 | 0.80 | TYK2 (0.67) | TYK2JAK1PDE4D | |
| SCHEMBL22342896 | 0.78 | KDM4E (0.50) | TYK2PDE4D | |
| SCHEMBL20689010 | 0.78 | TYK2 (0.44) | TYK2CYP1A1HPGDLMNA | |
| SCHEMBL22343302 | 0.78 | TYK2 (0.64) | TYK2JAK1 | |
| SCHEMBL22342930 | 0.78 | TYK2 (0.39) | TYK2 | |
| SCHEMBL22342918 | 0.77 | TYK2 (0.76) | TYK2 | |
| SCHEMBL22343286 | 0.77 | TYK2 (0.72) | TYK2JAK1PDE4D | |
| SCHEMBL29746683 | 0.77 | TYK2 (0.61) | TYK2JAK1 | |
| SCHEMBL21947188 | 0.76 | TYK2 (0.61) | TYK2 | |
| SCHEMBL22342884 | 0.75 | TYK2 (0.66) | TYK2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135567-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220135567-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3920931-A1 | TYK2 PSEUDOKINASE LIGANDS | Ventyx Biosciences, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163778-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163778-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135567-A1 | TYK2 PSEUDOKINASE LIGANDS | TYK2, JAK2, PTK2B | TYK2 1/4885CYP1A1 4674/4885HPGD 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.